MaxCyte expects core revenue for 2023 to be comparable to 2022 and Strategic Platform License program-related revenue expectations remain unchanged at approximately $6M for the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MXCT:
- MXCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MaxCyte signs strategic platform license with Prime MedicinePrime Medicine
- MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
- MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
- MaxCyte, Vittoria Biotherapeutics sign strategic platform license